Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease (AXemplify-357)

NCT06585774 is registered in ClinicalTrials.gov with Incyte Corporation as lead sponsor.

NCT NCT06585774
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06585774 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease (AXemplify-357)
Lead sponsor
Incyte Corporation
Phase
Phase 3
Overall status
Recruiting
Start date
January 21, 2025
Completion date
March 31, 2030
Enrollment
240 (estimated)
Sites
131

Conditions

As the registry lists them; a condition with its own page is linked.

chronic graft-versus-host-disease